Emin Can Ata1, Muharrem Şenel2. 1. Department of Cardiovascular Surgery, Private Eskişehir Anadolu Hospital, Eskişehir, Turkey. 2. Department of Cardiovascular Surgery, Private Su Hospital, İzmir, Turkey.
Abstract
BACKGROUND: In this study, we present our center's experience on percutaneous transluminal angioplasty/stenting. METHODS: Between January 2015 and March 2017, a total of 40 patients (34 males, 6 females; mean age 64.5±8.7 years; range, 49 to 85 years) who were treated in our clinic due to totally occluded iliofemoral artery disease were included. There were 45 legs and 51 targeted vessels. Hybrid procedure was performed to those patients with iliofemoral or femoropopliteal bypass grafts. RESULTS: A total of 48 target vessels (94.1%) were implanted using 55 stents at the initial attempt. Failed three target vessels (5.9%) were treated by surgical revascularization. There was no procedure-related mortality. Below-knee amputation was performed in one patient after 70 days. Two patients underwent single-finger amputation. Contrast nephropathy occurred in one patient and this patient was treated medically. The mean follow-up was 16.7±5 (range, 8 to 29) months. After follow-up, 41 stents were found to be patent without any intervention, and the primary patency rate was 74.5%. Five stent thrombosis patients (12.5%) were treated at different times. CONCLUSION: Our study results suggest that percutaneous transluminal angioplasty/stent treatment may be advisable in patients with significant comorbidities. The lower rates of complication in the stent series strongly suggest that, in experienced hands, percutaneous transluminal angioplasty/stent can offer lower procedural risks than surgical revascularization. Hybrid procedure is likely to be a reasonable choice for previously intervened comorbid patients for limb salvage.
BACKGROUND: In this study, we present our center's experience on percutaneous transluminal angioplasty/stenting. METHODS: Between January 2015 and March 2017, a total of 40 patients (34 males, 6 females; mean age 64.5±8.7 years; range, 49 to 85 years) who were treated in our clinic due to totally occluded iliofemoral artery disease were included. There were 45 legs and 51 targeted vessels. Hybrid procedure was performed to those patients with iliofemoral or femoropopliteal bypass grafts. RESULTS: A total of 48 target vessels (94.1%) were implanted using 55 stents at the initial attempt. Failed three target vessels (5.9%) were treated by surgical revascularization. There was no procedure-related mortality. Below-knee amputation was performed in one patient after 70 days. Two patients underwent single-finger amputation. Contrast nephropathy occurred in one patient and this patient was treated medically. The mean follow-up was 16.7±5 (range, 8 to 29) months. After follow-up, 41 stents were found to be patent without any intervention, and the primary patency rate was 74.5%. Five stent thrombosis patients (12.5%) were treated at different times. CONCLUSION: Our study results suggest that percutaneous transluminal angioplasty/stent treatment may be advisable in patients with significant comorbidities. The lower rates of complication in the stent series strongly suggest that, in experienced hands, percutaneous transluminal angioplasty/stent can offer lower procedural risks than surgical revascularization. Hybrid procedure is likely to be a reasonable choice for previously intervened comorbid patients for limb salvage.
Authors: R Mehran; G Dangas; A S Abizaid; G S Mintz; A J Lansky; L F Satler; A D Pichard; K M Kent; G W Stone; M B Leon Journal: Circulation Date: 1999-11-02 Impact factor: 29.690
Authors: Dariusz Janczak; Maciej Malinowski; Wojciech Bąkowski; Katarzyna Krakowska; Karol Marschollek; Paweł Marschollek; Mariusz Chabowski Journal: Ann Thorac Cardiovasc Surg Date: 2017-05-11 Impact factor: 1.520
Authors: Arnold H Seto; Mazen S Abu-Fadel; Jeffrey M Sparling; Soni J Zacharias; Timothy S Daly; Alexander T Harrison; William M Suh; Jesus A Vera; Christopher E Aston; Rex J Winters; Pranav M Patel; Thomas A Hennebry; Morton J Kern Journal: JACC Cardiovasc Interv Date: 2010-07 Impact factor: 11.195
Authors: Lucía Cea Soriano; F Gerry R Fowkes; Saga Johansson; Alaster M Allum; Luis A García Rodriguez Journal: Eur J Prev Cardiol Date: 2017-10-20 Impact factor: 7.804